Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jphp.13273 http://scihub22266oqcxt.onion/10.1111/jphp.13273 32301512!7262062!32301512     free     free     free       J+Pharm+Pharmacol 2020 ; 72 (9): 1145-1151 Nephropedia Template TP {{tp|p=32301512|t=2020. Drug repositioning: a brief overview |pdf=|usr=}}{{32301512}} gab.com Text Drug repositioning: a brief overview JO: J Pharm Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32301512 #FOAvip OBJECTIVES: Drug repositioning, that is, the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend. Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery. KEY FINDINGS: Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a number of recent successes have confirmed both its public health benefits and its commercial value. The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate. CONCLUSION: The history of great-repositioned drugs has given some solutions to various pathologies. Serendipity is not yet useful to find repositioning drugs. Drug repositioning is of growing interest. Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, especially using data mining. Twit Text FOAVip Drug repositioning: a brief overview ????J Pharm Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32301512 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32301512 #FOAvip English Wikipedia <ref>{{Cite pmid|32301512}}</ref> Drug repositioning: a brief overview #MMPMID32301512 Jourdan JP; Bureau R; Rochais C; Dallemagne P J Pharm Pharmacol 2020[Sep]; 72 (9): 1145-1151 PMID32301512show ga OBJECTIVES: Drug repositioning, that is, the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend. Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery. KEY FINDINGS: Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a number of recent successes have confirmed both its public health benefits and its commercial value. The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate. CONCLUSION: The history of great-repositioned drugs has given some solutions to various pathologies. Serendipity is not yet useful to find repositioning drugs. Drug repositioning is of growing interest. Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, especially using data mining. |*Data Mining[MESH] |Drug Discovery/*methods[MESH] |Drug Repositioning/economics/history/*methods[MESH] |History, 19th Century[MESH] |History, 20th Century[MESH] |History, 21st Century[MESH]Drug repositioning: a brief overview (epmc).pdf DeepDyve Pubget Overpricing